ERBB2 and neoplasm: Tumors of the youngest patient group displayed a higher proportion of molecular subtypes known to be associated with higher tumor aggressiveness, such as HER2-enriched and basal-like molecular subtypes, and lower ER protein and ESR1- and PGR mRNA gene expression levels, compared to older patients.